×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Non-Hodgkin Lymphoma

Brielle Urciuoli
Dewayne Johnson is the first of hundreds of patients to take Monsanto to trial, claiming that Roundup caused them to get cancer. His case will be seen even sooner than others because in California dying plaintiffs can be given expedited trials.
The FDA has granted an accelerated approval to Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or those who have relapsed after 2 or more prior lines of therapy.
Ryan Hamner
This is what surviving cancer sounds like.
Kristie L. Kahl
In this week’s episode of CURE Talks Cancer, we spoke with Matt Lashey, creator and CEO of the chemoWave app, which is designed to manage cancer symptoms and conditions by keeping track of a patient’s overall well-being to understand how their experiences may be related to feeling better or worse during treatment. 
Jessica Skarzynski
Thanks to genomic analysis by scientists at the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, diffuse large B cell lymphoma (DLBCL) is now a little easier to understand – and possibly easier to treat.
Shira Zwebner
Cancer has a profound effect on the youngest members of the family, especially when you go from swim Mom to sick Mom overnight.
Kristie L. Kahl
The chemoWave app, launched in July 2017, is designed to manage cancer symptoms and conditions by keeping track of a patient’s overall well-being.
Beth Incollingo
Yescarta was granted FDA approval for use in adults with relapsed or refractory non-Hodgkin lymphoma. This is only the second CAR T-cell therapy ever approved.
Allie Casey
Jessica Yasmine Islam, M.P.H., discusses the changing statistics behind people with HIV and cancer.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other